Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Citius Pharmaceuticals, Inc. on May 1, 2015, reporting events that occurred between March 20, 2015, and April 30, 2015. The company is incorporated in Nevada and is based in Maynard, MA.
Key Financial Metrics
The filing details a private placement transaction resulting in gross proceeds of $740,000. The company issued 1,370,000 shares of common stock and 1,370,000 warrants to two accredited investors. No commissions were paid in connection with these sales. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in equity capital through the unregistered sale of securities. The company issued 1,370,000 shares and an equal number of warrants exercisable at $0.60 per share with a five-year term. Holders of these securities have been granted registration rights.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the issuances were made in reliance on the Section 4(a)(2) exemption from registration under the Securities Act of 1933. There are no unusual items or contingencies reported in this document.
Key Facts for Investor Verification
- Verify the total gross proceeds of $740,000 received from the private placement.
- Confirm the issuance of 1,370,000 common shares and 1,370,000 warrants.
- Note the warrant exercise price of $0.60 per share and the five-year term.
- Check for the existence of registration rights granted to the investors.
- Confirm that no underwriting commissions were paid on this transaction.